Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the ...

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...

Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate ...

In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the National Institutes of Health concerning royalties and other related amounts allegedly ...

Recent health developments include the FDA's approval of an injectable version of Bristol Myers Squibb's cancer drug Opdivo.

The ADR's fall snapped a three-day winning streak.

Dec 27 (Reuters) - BioNTech (22UAy.DE), opens new tab has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the ...